SCHEMBL5367565

SCHEMBL5367565

CCOP(=O)(OCC)C(NCc1cccnc1)P(=O)(OCC)OCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
PKM P14618 1/20 0.50
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
ALDH1A1 P00352 3/20 0.47
POLB P06746 3/20 0.47
TP53 P04637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MEN1 O00255 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
HPGD P15428 1/20 0.43
GAA P10253 1/20 0.43
TSHR P16473 2/20 0.43
RECQL P46063 1/20 0.42
FDPS P14324 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14064101 0.82 MEN1 (0.62) KMT2ALMNAALDH1A1POLBNPSR1
SCHEMBL6060892 0.78 FDPS (0.60) KMT2APKMLMNAMAPK1ALDH1A1
SCHEMBL5366533 0.77 FDPS (0.59) PKMLMNAALDH1A1POLBCYP1A2
SCHEMBL18307753 0.76 FDPS (0.43) KMT2APKMLMNAMAPK1ALDH1A1
SCHEMBL8003353 0.75 HMGCR (0.47) KMT2APKMLMNAMAPK1ALDH1A1
SCHEMBL5363346 0.73 ALDH1A1 (0.44) KMT2AALDH1A1POLBNPSR1MEN1
SCHEMBL578225 0.73 FDPS (0.45) KMT2APKMLMNAMAPK1ALDH1A1
SCHEMBL27517905 0.73 FDPS (0.50) KMT2APKMLMNAMAPK1ALDH1A1
SCHEMBL8170743 0.73 FDPS (0.61) KMT2APKMLMNAMAPK1POLB
SCHEMBL19334562 0.72 CYP1A2 (0.58) KMT2APKMALDH1A1POLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208481-B2 Aminodiphosphonate apolipoprotein E modulators ILEX PRODUCTS, INC. (US) 2007-04-24 US claimed
US-20050075317-A1 Aminodiphosphonate apolipoprotein e modulators PHAN HIEU TRUNG (CH) 2005-04-07 US claimed
EP-1482897-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS Ilex Products, Inc. (US) 2004-12-08 EP claimed
WO-2003070169-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS ILEX PRODUCTS, INC. (US) 2003-08-28 WO claimed
US-7208481-B2 Aminodiphosphonate apolipoprotein E modulators ILEX PRODUCTS, INC. (US) 2007-04-24 US disclosed
US-20050075317-A1 Aminodiphosphonate apolipoprotein e modulators PHAN HIEU TRUNG (CH) 2005-04-07 US disclosed
EP-1482897-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS Ilex Products, Inc. (US) 2004-12-08 EP disclosed
WO-2003070169-A2 AMINODIPHOSPHONATE APOLIPOPROTEIN E MODULATORS ILEX PRODUCTS, INC. (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075317-A1 Aminodiphosphonate apolipoprotein e modulators APOB, APOL1, NAPEPLD KMT2A 3444/4885PKM 2284/4885LMNA 2383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.